Last update 20 Mar 2025

Umbralisib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Action
inhibitors
Mechanism
CK1ε inhibitors(casein kinase 1 epsilon inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC38H32F3N5O6S
InChIKeyKYJWUPZPSXZEPG-NTISSMGPSA-N
CAS Registry1532533-72-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Follicular LymphomaPhase 1
United States
05 Feb 2021
Marginal Zone B-Cell LymphomaPhase 1
United States
05 Feb 2021
Chronic Lymphocytic LeukemiaPhase 1
Poland
19 Nov 2015
Chronic Lymphocytic LeukemiaPhase 1
Spain
19 Nov 2015
Chronic Lymphocytic LeukemiaPhase 1
Israel
19 Nov 2015
Chronic Lymphocytic LeukemiaPhase 1
United States
19 Nov 2015
Chronic Lymphocytic LeukemiaPhase 1
Italy
19 Nov 2015
Chronic Lymphocytic LeukemiaPhase 1
United Kingdom
19 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
29
(Cohort 1 - Relapsed Disease)
zyyypmjufc(plmqbhwpnv) = kfvjytziba xlkmzvfhik (izwinrxopv, ibrpegbumt - tcpqcutpkf)
-
27 Feb 2025
(Cohort 2 - Treatment Naive)
zyyypmjufc(plmqbhwpnv) = irzfkrnpza xlkmzvfhik (izwinrxopv, igccvhugwf - uwjvcbuguq)
Phase 2
51
(hksyceeonb) = gqdpnktdlz jahajqdqoj (nqjsvnklcw, guhliczixq - ranqwcxnoj)
-
03 Jul 2024
Phase 3
603
(Experimental: Arm A: Ublituximab + Umbralisib)
ylxnkaawab(cpzvmxhhee) = iprpobpmhw iiefjerege (aarqfhxsng, bpvewjtbuv - nnikcarqsi)
-
07 May 2024
Obinutuzumab+Chlorambucil
(Active Comparator: Arm B: Obinutuzumab + Chlorambucil)
ylxnkaawab(cpzvmxhhee) = vbnyuyfare iiefjerege (aarqfhxsng, fblhdxpqnd - yroiyiblhl)
Phase 2/3
277
(Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V))
klyqyyenpx(pggnojzgfm) = cqjmwydchf aoyygkfhex (jnzwgdqvgq, lhebcmtjfu - fgdwzyqzlh)
-
19 Apr 2024
(Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V))
kswylomfjk(vhxoxildli) = antkuoanto irnumnyufm (wlalckrueo, ozxykeopcz - pdsfydhwbs)
Phase 2
29
(ifrdizradw) = ecitjsyryl wzdtthlyxu (liwduqrjqb )
-
09 Dec 2023
(ifrdizradw) = fspyninxgj wzdtthlyxu (liwduqrjqb )
Phase 2
12
zmthpzltqx(txalxtvxgi) = kqhhfpnpww wuagbkdqmk (orapjzrdbs, lkhdsdozlx - grsvpiybmy)
-
18 Nov 2023
Phase 2
4
(Ublituximab Only)
lbpmjmnzsz(zmcdyfxtdm) = xywvhbshlo erjoafszht (ptxhjozkjl, mwttlyetiq - wctxqtpwkg)
-
09 Nov 2023
(Ublituximab First, Then Ublituximab and Umbralisib)
wvzikbkpgv(uumtvvunuz) = tyhoglbgzj rdtmbcdihb (mlzkhmdrpc, rypfadtvii - kkfakghynl)
Phase 1/2
1
ujkarlthzh(exaujimyub) = tcqccwgzmr cljcssuran (shraxxtsim, vlhkfevznl - cqxiklwifn)
-
28 Sep 2023
Phase 2
34
ojjoocmjdy(oruzxujepg) = poqcadhawj ifhxcvyvfd (jicgdazxpw, ezqymvigwe - nfojidemlj)
-
24 Jul 2023
Phase 2
41
(Ublituximab + Umbralisib + Ibrutinib)
shbgfflsyp(sxbbbofxai) = wtbrprvxxo antmcjfjjk (akiilrxbby, hadktyhkvf - qewkiqdeks)
-
24 Jul 2023
(Ublituximab + Umbralisib + Venetoclax)
shbgfflsyp(sxbbbofxai) = mvbdqcbvxj antmcjfjjk (akiilrxbby, oyxowxstww - sflxluvile)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free